Charlie Schmidt

Charlie Schmidt is an award-winning freelance science writer based in Portland, Maine. In addition to writing for Harvard Health Publishing, Charlie has written for Science magazine, the Journal of the National Cancer Institute, Environmental Health Perspectives, Nature Biotechnology, and The Washington Post.


Posts by Charlie Schmidt

New study once again casts doubt on PSA screening

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

The largest study to date of prostate cancer screening reinforces the existing evidence that the potential benefits of the test are outweighed by the harms of overtreatment for low-grade cancer that could be left untreated.

A mix of treatments may extend life for men with aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Combining multiple forms of radiation therapy with hormone treatments lengthens survival in men with aggressive prostate cancer.

FDA approves new drug for men at high risk of prostate cancer spread

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men whose PSA levels continue rising even after surgery or radiation therapy may have a new treatment option with the approval of the drug apalutamide.

Newer drugs are improving survival for men with metastatic prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with prostate cancer that has spread outside the gland now have several newer drug options available for treatment, and research has found that taking any of them is likely to improve survival duration.

Study investigates treatment regret among prostate cancer survivors

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Surveys of over 900 men who were diagnosed with prostate cancer in the 1990s found that approximately 15% had some regret over their treatment choices. Study authors encourage doctors and patients to have frank and thorough discussions about about the risks and benefits of various forms of treatment for prostate cancer.

Strong study shows no link between vasectomy and prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

In contrast to earlier research, a review of dozens of studies involving millions of men who had vasectomies found no proof that having a vasectomy increases a man’s risk of prostate cancer.

Combination hormonal therapy boosts survival in men with aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

The results of two studies found that using the drug abiraterone in combination with other hormonal therapy drugs to treat aggressive prostate cancer produced more favorable results than the first-line therapy alone.

Yoga improves treatment-related symptoms in men with prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men who participated in yoga classes twice a week while being treated for prostate cancer reported less fatigue and better urinary and erectile function, compared to other men in the study who did not do yoga.

Combining surgery, radiation, and hormonal therapy dramatically extends survival in men with advanced prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

A small pilot study that combined surgery, radiation, and hormone therapy may lead to future treatment options for men with prostate cancer that has spread beyond the gland.

Adding hormonal therapy to radiation lengthens survival in men with recurring prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

For men who have had prostate gland removal surgery, results from a new study show that a combination of radiation treatment and androgen deprivation therapy is more effective for treating PSA recurrence than radiation alone.